Jaguar Animal Health announced Thursday that during a pilot study of its treatment Canalevia to treat diarrhea, 91% of dogs who received the drug responded positively to it, vs. 50% of dogs who were given a placebo. Canalevia, derived from a compound in Croton lechleri trees, is Jaguar's lead prescription drug candidate and a canine-specific version of Fulyzaq (crofelemer), which was approved by the FDA in 2012 for HIV patients. Fulyzaq is made by Napo Pharmaceuticals--Jaguar's majority shareholder. Jaguar plans to use the Canalevia study results to design a pivotal trial in dogs, which the company expects to complete this year. Release